Overview

Clinical Pharmacology of FYU-981 (Subjects With Hepatic Insufficiency)

Status:
Completed
Trial end date:
2018-06-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the pharmacokinetics, pharmacodynamics and safety after single oral administration of FYU-981 to subjects with hepatic insufficiency and with normal hepatic function.
Phase:
Phase 1
Details
Lead Sponsor:
Mochida Pharmaceutical Company, Ltd.
Collaborator:
Fuji Yakuhin Co., Ltd.
Treatments:
Dotinurad